Soft Tissue Sarcomas Market by Treatment Type, Disease Type, End User, Therapy Type, Distribution Channel - Global Forecast 2025-2030- Product Image

New

Soft Tissue Sarcomas Market by Treatment Type, Disease Type, End User, Therapy Type, Distribution Channel - Global Forecast 2025-2030

Report
199 Pages
October 2024
Region: Global
360iResearch™
ID: 6011940

The Soft Tissue Sarcomas Market grew from USD 672.82 million in 2023 to USD 730.82 million in 2024. It is expected to continue growing at a CAGR of 9.65%, reaching USD 1.28 billion by 2030.

Soft Tissue Sarcomas (STS) encompass a heterogeneous group of cancers that originate from connective tissues such as fat, muscle, and nerves, representing a small percentage of adult malignancies yet posing significant oncological challenges. The market for STS treatment is driven by increasing incidence rates, enhanced diagnostic techniques, and the rise of advanced therapies, including targeted drugs and immunotherapies. The scope involves pharmaceuticals, diagnostics, and therapeutics, with end-use applications spanning hospitals, specialized cancer clinics, and research institutions. Continuous innovation in early diagnosis and treatment methodology is imperative due to the historical reliance on surgery, radiation, and chemotherapy, each with limited efficacy. Key growth factors include rising healthcare expenditure, governmental support for cancer research, and advancements in molecular biology leading to novel treatments. Opportunities lie in the development of personalized medicine approaches and the integration of artificial intelligence in diagnosis and treatment planning, which could streamline costs and improve patient outcomes. However, challenges such as the rarity of the condition, leading to fewer clinical trials and limited patient pools, make drug development and market penetration difficult. Regulatory approvals and high treatment costs further complicate the market landscape, particularly in low-income regions. Innovation can be steered towards drug delivery systems to enhance therapeutic uptake and precision in targeting cancer cells, as well as the exploration of combination therapies to overcome drug resistance. Speeding up the clinical trials through adaptive trial designs and promoting collaborations among pharmaceutical companies and research institutes can facilitate growth. As the market trends towards precision oncology, understanding genetic and enzymatic pathways unique to STS will open new horizons for treatment modalities. The inherently niche yet evolving nature of the STS market demands a focus on education and awareness to increase early diagnosis, thereby expanding market reach and impacting overall prognosis favorably.

Understanding Market Dynamics in the Soft Tissue Sarcomas Market

The Soft Tissue Sarcomas Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of soft tissue sarcomas leading to demand for effective treatments
- Technological advancements in diagnostic tools improving early detection rates and patient outcomes
- Rising awareness and government initiatives promoting early diagnosis and treatment of soft tissue sarcomas
- Significant investments in research and development activities for innovative treatment options
Market Restraints
- Limited availability and high cost of advanced diagnostic tools for soft tissue sarcomas
Market Opportunities
- Expansion of advanced therapeutic options for soft tissue sarcoma treatment
- Increasing investment in research and development for soft tissue sarcoma therapies
- Rising awareness and early diagnosis initiatives to improve soft tissue sarcoma patient outcomes
Market Challenges
- Fragmentation of soft tissue sarcoma treatment leading to varied management practices worldwide

Exploring Porter’s Five Forces for the Soft Tissue Sarcomas Market

Porter’s Five Forces framework further strengthens the insights of the Soft Tissue Sarcomas Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Soft Tissue Sarcomas Market

External macro-environmental factors deeply influence the performance of the Soft Tissue Sarcomas Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Soft Tissue Sarcomas Market

The Soft Tissue Sarcomas Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Soft Tissue Sarcomas Market

The Soft Tissue Sarcomas Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Soft Tissue Sarcomas Market

The Soft Tissue Sarcomas Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Soft Tissue Sarcomas Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Soft Tissue Sarcomas Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Type
- Chemotherapy
- Combination Therapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Targeted Therapy
Disease Type
- Angiosarcoma
- Clear Cell Sarcoma
- Desmoplastic Small-Round-Cell Tumor
- Ewing's Sarcoma
- Gastrointestinal Stromal Tumors
- Leiomyosarcoma
- Liposarcoma
  - Dedifferentiated Liposarcoma
  - Mixed-Type Liposarcoma
  - Myxoid Liposarcoma
  - Pleomorphic Liposarcoma
  - Well-Differentiated Liposarcoma
- Malignant Peripheral Nerve Sheath Tumors
- Rhabdomyosarcoma
  - Alveolar Rhabdomyosarcoma
  - Anaplastic Rhabdomyosarcoma
  - Embryonal Rhabdomyosarcoma
- Synovial Sarcoma
End User
- Ambulatory Surgical Centers
- Cancer Treatment and Research Centers
- Clinics
- Hospitals
  - Private Hospitals
  - Public Hospitals
Therapy Type
- First-Line Therapy
- Fourth-Line Therapy and Above
- Second-Line Therapy
- Third-Line Therapy
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of soft tissue sarcomas leading to demand for effective treatments
5.1.1.2. Technological advancements in diagnostic tools improving early detection rates and patient outcomes
5.1.1.3. Rising awareness and government initiatives promoting early diagnosis and treatment of soft tissue sarcomas
5.1.1.4. Significant investments in research and development activities for innovative treatment options
5.1.2. Restraints
5.1.2.1. Limited availability and high cost of advanced diagnostic tools for soft tissue sarcomas
5.1.3. Opportunities
5.1.3.1. Expansion of advanced therapeutic options for soft tissue sarcoma treatment
5.1.3.2. Increasing investment in research and development for soft tissue sarcoma therapies
5.1.3.3. Rising awareness and early diagnosis initiatives to improve soft tissue sarcoma patient outcomes
5.1.4. Challenges
5.1.4.1. Fragmentation of soft tissue sarcoma treatment leading to varied management practices worldwide
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Soft Tissue Sarcomas Market, by Treatment Type

6.1. Introduction
6.2. Chemotherapy
6.3. Combination Therapy
6.4. Immunotherapy
6.5. Radiation Therapy
6.6. Surgery
6.7. Targeted Therapy

7. Soft Tissue Sarcomas Market, by Disease Type

7.1. Introduction
7.2. Angiosarcoma
7.3. Clear Cell Sarcoma
7.4. Desmoplastic Small-Round-Cell Tumor
7.5. Ewing's Sarcoma
7.6. Gastrointestinal Stromal Tumors
7.7. Leiomyosarcoma
7.8. Liposarcoma
7.8.1. Dedifferentiated Liposarcoma
7.8.2. Mixed-Type Liposarcoma
7.8.3. Myxoid Liposarcoma
7.8.4. Pleomorphic Liposarcoma
7.8.5. Well-Differentiated Liposarcoma
7.9. Malignant Peripheral Nerve Sheath Tumors
7.10. Rhabdomyosarcoma
7.10.1. Alveolar Rhabdomyosarcoma
7.10.2. Anaplastic Rhabdomyosarcoma
7.10.3. Embryonal Rhabdomyosarcoma
7.11. Synovial Sarcoma

8. Soft Tissue Sarcomas Market, by End User

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Cancer Treatment and Research Centers
8.4. Clinics
8.5. Hospitals
8.5.1. Private Hospitals
8.5.2. Public Hospitals

9. Soft Tissue Sarcomas Market, by Therapy Type

9.1. Introduction
9.2. First-Line Therapy
9.3. Fourth-Line Therapy and Above
9.4. Second-Line Therapy
9.5. Third-Line Therapy

10. Soft Tissue Sarcomas Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Soft Tissue Sarcomas Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Soft Tissue Sarcomas Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Soft Tissue Sarcomas Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

LIST OF FIGURES

FIGURE 1. SOFT TISSUE SARCOMAS MARKET RESEARCH PROCESS
FIGURE 2. SOFT TISSUE SARCOMAS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. SOFT TISSUE SARCOMAS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. SOFT TISSUE SARCOMAS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. SOFT TISSUE SARCOMAS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. SOFT TISSUE SARCOMAS MARKET DYNAMICS
TABLE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CLEAR CELL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DESMOPLASTIC SMALL-ROUND-CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY EWING'S SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DEDIFFERENTIATED LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MIXED-TYPE LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MYXOID LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PLEOMORPHIC LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY WELL-DIFFERENTIATED LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALVEOLAR RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANAPLASTIC RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY EMBRYONAL RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER TREATMENT AND RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FOURTH-LINE THERAPY AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THIRD-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 79. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 80. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 81. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 88. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 89. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 121. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 122. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 123. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 125. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 126. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 130. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 131. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 133. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 134. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 146. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 147. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 149. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 150. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 193. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 194. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 195. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 198. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 201. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 202. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 203. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 216. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 219. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 220. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 223. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 226. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 227. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 228. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 230. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 231. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 234. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 235. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 236. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 238. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 239. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 242. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 243. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 244. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 247. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 251. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 252. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 254. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 255. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 266. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 267. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 268. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 271. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 290. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 291. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 292. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 294. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 295. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 298. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 299. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 300. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 302. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 303. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 305. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 306. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 307. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 308. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 310. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 311. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 313. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 314. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 315. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 316. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 318. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 319. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 322. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 324. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 330. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
TABLE 332. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 333. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 334. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 336. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 337. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 338. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
TABLE 339. S

Companies Mentioned

The leading players in the Soft Tissue Sarcomas market, which are profiled in this report, include:

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Blueprint Medicines Corporation
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
GlaxoSmithKline plc
Ipsen Biopharmaceuticals, Inc.
Johnson & Johnson
Kyowa Kirin Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	199
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 730.82 Million
Forecasted Market Value ( USD ) by 2030	$ 1280 Million
Compound Annual Growth Rate	9.6%
Regions Covered	Global
No. of Companies Mentioned	21

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3743EUR$3,939USD£3,119GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6623EUR$6,969USD£5,518GBP

Understanding Market Dynamics in the Soft Tissue Sarcomas Market

Exploring Porter’s Five Forces for the Soft Tissue Sarcomas Market

Applying PESTLE Analysis to the Soft Tissue Sarcomas Market

Analyzing Market Share in the Soft Tissue Sarcomas Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Soft Tissue Sarcomas Market

Strategic Recommendations for Success in the Soft Tissue Sarcomas Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030

Sarcoma Drugs Market By Disease Indication, By Treatment, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031

Soft Tissue Sarcoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Soft Tissue Sarcoma - Market Insight, Epidemiology and Market Forecast - 2034

Soft Tissue Sarcoma (STS) with lung metastases - Market Insight, Epidemiology and Market Forecast -2032